Endo Reinforces Commitment To Pain With Novel Phase II Drug License
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo licenses axomadol for chronic pain and diabetic neuropathic pain from Grunenthal; sNDA for Valstar in bladder cancer also approved.
You may also be interested in...
Endo Plans Valstar Relaunch In Second Half
Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.
Endo Plans Valstar Relaunch In Second Half
Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.
Endo Branches Out With $370M Indevus Acquisition
Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.